Nemiralisib - GlaxoSmithKline

Drug Profile

Nemiralisib - GlaxoSmithKline

Alternative Names: [14C]-GSK2269557; GSK 2269557; GSK 2269557 ELLIPTA DPI

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiasthmatics; Indazoles; Indoles; Oxazoles; Piperazines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease; Immunodeficiency disorders

Most Recent Events

  • 28 Nov 2017 Phase-II clinical trials in Chronic obstructive pulmonary disease in Sweden, Poland, USA (Inhalation) (EudraCT2017-001074-42) (NCT03345407)
  • 28 Nov 2017 GlaxoSmithKline initiates enrolment in a phase II trial for Chronic obstructive pulmonary disease in Canada, Germany, Romania, Russia (Inhalation) (EudraCT2017-001074-42) (NCT03345407)
  • 14 Nov 2017 Phase-I clinical trials in Chronic obstructive pulmonary disease (In volunteers) in United Kingdom (IV) (NCT03315559)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top